Term
| HMG-CoA reductase inhibitors (statins) |
|
Definition
| MOA: decrease cholesterol by inhibiting HMG-CoA reductase in the liver |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| cholesterol absorption inhibitor |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| cholesterol absorption inhibitor |
|
Definition
| MOA: inhibits uptake of cholesterol by binding to NPC1L1 and decreasing LDL cholesterol |
|
|
Term
|
Definition
| MOA: complexes with bile acids secreted from liver into small intestines and can then be excreted |
|
|
Term
|
Definition
| MOA: bind to and activate PPAR-a, resulting in changes on lipid metabolism |
|
|
Term
|
Definition
| MOA: inhibits the formation and secretion of hepatic VLDL; increases the plasma HDL by increasing the half-life of apo A-1 |
|
|
Term
|
Definition
| MOA: inhibits binding of PCSK9 to LDLR |
|
|
Term
|
Definition
| MOA: decreases synthesis of chylomicrons and VLDL, leading to decreased plasma LDL |
|
|
Term
|
Definition
| MOA: inhibits synthesis of apo B-100, leading to decreased LDL |
|
|
